Aprea Therapeutics (NASDAQ: APRE) wins 180-day extension to meet $1 bid
Rhea-AI Filing Summary
Aprea Therapeutics, Inc. received a notification from Nasdaq on July 23, 2026 that it qualifies for an additional 180-day Second Compliance Period, through January 19, 2027, to regain compliance with the Nasdaq Capital Market Minimum Bid Price Requirement of at least $1.00 per share under Listing Rule 5550(a)(2).
The company had previously been given until July 22, 2026 to restore compliance after its common stock fell below the $1.00 minimum bid price. If at any time during the Second Compliance Period the closing bid price of the common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will confirm compliance. If compliance is not demonstrated by January 19, 2027, Nasdaq states it will issue a notice of delisting, which Aprea could then appeal to a hearings panel.
Positive
- None.
Negative
- Risk of Nasdaq delisting if Aprea has not met the $1.00 minimum bid price requirement for 10 consecutive business days by January 19, 2027, after which Nasdaq indicates it will issue a delisting notice.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Key Figures
Second Compliance Period length: 180 calendar days
Second Compliance Period end date: January 19, 2027
Minimum Bid Price Requirement: $1.00 per share
+2 more
5 metrics
Second Compliance Period length
180 calendar days
Additional period granted by Nasdaq to regain the $1.00 minimum bid price
Second Compliance Period end date
January 19, 2027
Final date to demonstrate compliance with Nasdaq Minimum Bid Price Requirement
Minimum Bid Price Requirement
$1.00 per share
Required minimum closing bid price for continued listing on the Nasdaq Capital Market
Required compliance streak
10 consecutive business days
Length of time the closing bid must be at or above $1.00 to regain compliance
Initial compliance deadline
July 22, 2026
End of first 180-day period after the January 23, 2026 Nasdaq deficiency notice
Key Terms
Minimum Bid Price Requirement, Nasdaq Listing Rule 5550(a)(2), Nasdaq Listing Rule 5810(c)(3)(A), Second Compliance Period
4 terms
Minimum Bid Price Requirement regulatory
"regain compliance with the $1.00 minimum bid price required for continued listing"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2)"
Nasdaq Listing Rule 5810(c)(3)(A) regulatory
"pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was initially provided 180 days"
Second Compliance Period regulatory
"eligible for an additional 180 calendar day period, or until January 19, 2027, the Second Compliance Period"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Aprea Therapeutics (APRE) report about its Nasdaq listing status?
Aprea Therapeutics reported that Nasdaq granted an additional 180-day Second Compliance Period, until January 19, 2027, to regain compliance with the $1.00 minimum bid price required for continued listing on the Nasdaq Capital Market.
Until when does Aprea Therapeutics (APRE) have to regain Nasdaq bid price compliance?
Aprea Therapeutics has until January 19, 2027 to regain compliance. This Second Compliance Period extends the original deadline of July 22, 2026 that followed Nasdaq’s January 23, 2026 deficiency notice.
What is the Nasdaq minimum bid price requirement affecting Aprea Therapeutics (APRE)?
Nasdaq’s rule requires Aprea’s common stock to maintain a minimum bid price of $1.00 per share. To regain compliance, the closing bid must be at least $1.00 for 10 consecutive business days during the Second Compliance Period.
What happens if Aprea Therapeutics (APRE) does not meet Nasdaq’s bid price rule by January 19, 2027?
If Aprea has not regained the $1.00 minimum bid price by January 19, 2027, Nasdaq states it will provide written notification that the common stock will be delisted. Aprea may then appeal this determination to a Nasdaq hearings panel.
Why did Aprea Therapeutics (APRE) originally receive a Nasdaq deficiency notice?
On January 23, 2026, Aprea received a Nasdaq deficiency notice because its common stock failed to comply with the $1.00 minimum bid price requirement. Nasdaq initially granted 180 days, until July 22, 2026, to regain compliance under Listing Rule 5810(c)(3)(A).